| External factors: | Metformin |
| Aging type: | Accelerate |
| Aging characteristic: |
| Category: | Chemical compounds |
| Phenotype: | Hepatocellular carcinoma |
| Experiment: | SA-β-gal activity assay//Immunostaining |
| Description: | The SA-β-gal staining was significantly higher in the treated group than in the control group.immunohistochemical analysis of the harvested tumors revealed increased DEC1 expression compared with the control animals. |
| Regulatory pathway: | AMPK-SIRT1 |
| R-EF-Pathway: | Activation |
| Official symbol(s): | AMPK-SIRT1 |
| Pathway experiment: | Immunostaining//Western blot |
| Pathway description: | Immunohistochemistry analysis revealed increased positive staining of pAMPK at Thr-172, pSIRT1 at Ser-47, acetylated-p53 at Lys382 (Ac-p53) and p21 in harvested tumors from low-dose-metformin-treated animals compared with control animals , which is consistent with the western blot analysis results. |
Annotation: